Evaluation of prostatic artery embolization efficiency in benign prostatic hyperplasia patients withhigh comorbidity
| dc.contributor.author | Yildirim, Ismail Okan | |
| dc.contributor.author | Duman, Enes | |
| dc.contributor.author | Firat, Ali | |
| dc.contributor.author | Celik, Huseyin | |
| dc.contributor.author | Sarac, Kaya | |
| dc.date.accessioned | 2019-07-11T10:47:49Z | |
| dc.date.available | 2019-07-11T10:47:49Z | |
| dc.date.issued | 2018 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | Objective: The purpose of this study was to evaluate efficacy outcomes following prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) patients with high comorbidity. Materials and Methods: This retrospective study included 22 patients treated with PAE from May 2015 to June 2017. Patients with Charlson comorbidity index >= 2, International Prostate Symptom Score (IPSS) >12, prostate specific antigen (PSA) levels <4 ng/mL or between 4 and 10 ng/mL with negative prostate biopsy and total prostate volume (TPV) >90 cm(3) were included. Total PSA, maximum flow rate (Q(max)), TPV, IPSS, post-voiding residual (PVR) values were recorded in all patients in the urology clinic before PAE and at 3 and 6 months after PAE. Results: The average patient age was 73.86 +/- 6.25 years and operative time was 80 minutes (range, 60-120 min). Pre-PAE and 6-month post-PAE values were: IPSS: 25.18 +/- 6.75 an d 11.27 +/- 3.29 (p<0.05), Q(max): 8.31 +/- 3.12 and 17.22 +/- 3.23 (p<0.05), PVR: 87.9 +/- 19.25 and 25.86 +/- 7.72 (p<0.05), TPV: 134.45 +/- 57.56 and 86 +/- 15.4 (p<0.05), and PSA: 3.89 +/- 1.26 and 2.11 +/- 1.06 (p<0.05). Embolization was performed unilaterally due to atherosclerosis and strictures in the internal iliac artery branches in 2 patients. After the procedure, 2 patients experienced transient hematuria which did not require bladder irrigation, 1 patient had acute urinary retention due to dysuria, and 1 patient had transient hematospermia. Conclusion: PAE may be an alternative treatment method in BPH patients with high comorbidity. | en_US |
| dc.identifier.citation | Yildirim, IO . Duman, E. Firat, A. Celik, H. Sarac, K . (2018). Evaluation of prostatic artery embolization efficiency in benign prostatic hyperplasia patients withhigh comorbidity. Cilt:17. Sayı:1. 14-17 ss. | en_US |
| dc.identifier.doi | 10.4274/uob.937 | en_US |
| dc.identifier.endpage | 17 | en_US |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.startpage | 14 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/12530 | |
| dc.identifier.volume | 17 | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Galenos yayıncılık, erkan mor, molla guranı cad 21-1, fındıkzade, ıstanbul 34093, turkey | en_US |
| dc.relation.ispartof | Uroonkolojı bultenı-bulletın of urooncology | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Urınary-tract symptoms | en_US |
| dc.subject | mıdterm follow-up | en_US |
| dc.subject | transurethral resectıon | en_US |
| dc.subject | trıal | en_US |
| dc.subject | turp | en_US |
| dc.title | Evaluation of prostatic artery embolization efficiency in benign prostatic hyperplasia patients withhigh comorbidity | en_US |
| dc.type | Article | en_US |
